McInnes G T, Shelton J R, Ramsay L E, Harrison I R, Asbury M J, Clarke J M, Perkins R M, Venning G R
Br J Clin Pharmacol. 1982 Mar;13(3):331-9. doi: 10.1111/j.1365-2125.1982.tb01383.x.
1 The renal antimineralocorticoid potency of single doses of thirteen compounds with properties in animals compatible with competitive aldosterone antagonism was compared to that of spironolactone in healthy men. 2 Twelve compounds showed significant activity when compared to placebo but only one, prorenoate potassium, was significantly more potent than spironolactone on a weight basis. 3 The results allowed ranking of the compounds in order of potency relative to spironolactone and general observations on structure activity relationships in man. 4 Animal bioassays and in vitro aldosterone binding studies are unreliable predictors of the human activity of competitive mineralocorticoid antagonists.